AFVT 2101
Alternative Names: AFM-32; AFVT-2101Latest Information Update: 28 Dec 2024
At a glance
- Originator Affimed Therapeutics
- Developer Affivant Sciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Macrophage stimulants; Monocyte stimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 23 May 2023 Affivant plans a phase I trial for Solid tumours in 2023
- 14 Apr 2023 Pharmacokinetics and adverse events data from preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)